Gregory McInnes

Gregory McInnes

Auto-generated profile, based on publicly available information

Gregory McInnes

Stanford University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
GMGregory McInnes
Gregory McInnes
ALAdam Lavertu
Adam Lavertu
KSKatrin Sangkuhl
Katrin Sangkuhl
TKTeri E. Klein
Teri E. Klein
MWMichelle Whirl‐Carrillo
Michelle Whirl‐Carrillo
RARuss B Altman
Russ B Altman

5 December 2018 in Bioinformatics
Verified
Journal Article
Open access
PDF file
GMGregory McInnes
Gregory McInnes
Yosuke TanigawaYosuke Tanigawa
Yosuke Tanigawa
CDChris DeBoever
Chris DeBoever
ALAdam Lavertu
Adam Lavertu
JOJulia Eve Olivieri
Julia Eve Olivieri
MRmanuel rivas
manuel rivas
Large biobanks linking phenotype to genotype have led to an explosion of genetic association studies across a wide range of phenotypes. Sharing the knowledge generated by these resources with the scientific community remains a challenge due to patient privacy and the vast amount of data. Here, we present Global Biobank Engine (GBE), a web-based tool that enables exploration of the relationship between genotype and phenotype in biobank cohorts, such as the UK Biobank. GBE supports browsing for results from genome-wide association studies, phenome-wide association studies, gene-based tests and genetic correlation between phenotypes. We envision GBE as a platform that facilitates the dissemination of summary statistics from biobanks to the scientific and clinical communities. GBE currently hosts data from the UK Biobank and can be found freely available at biobankengine.stanford.edu.

2 November 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
GMGregory McInnes
Gregory McInnes
RDRachel Dalton
Rachel Dalton
KSKatrin Sangkuhl
Katrin Sangkuhl
MWMichelle Whirl-Carrillo
Michelle Whirl-Carrillo
SLSeung-Been Lee
Seung-Been Lee
EWErica Woodahl
Erica Woodahl
Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic gene whose protein product metabolizes more than 20% of clinically used drugs. Genetic variations inCYP2D6are responsible for interindividual heterogeneity in drug response that can lead to drug toxicity and ineffective treatment, makingCYP2D6one of the most important pharmacogenes. Prediction of CYP2D6 phenotype relies on curation of literature-derived functional studies to assign a functional status toCYP2D6haplotypes. As the number of large-scale sequencing efforts grows, new haplotypes continue to be discovered, and assignment of function is challenging to maintain. To address this challenge, we have trained a convolutional neural network to predict functional status ofCYP2D6haplotypes, called Hubble.2D6. Hubble.2D6 predicts haplotype function from sequence data and was trained using two pre-training steps with a combination of real and simulated data. We find that Hubble.2D6 predictsCYP2D6haplotype functional status with 88% accuracy in a held-out test set and explains 47.5% of the variance inin vitrofunctional data among star alleles with unknown function. Hubble.2D6 may be a useful tool for assigning function to haplotypes with uncurated function, and used for screening individuals who are at risk of being poor metabolizers.

7 November 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MKMegan L. Koleske
Megan L. Koleske
GMGregory McInnes
Gregory McInnes
JBJulia E. H. Brown
Julia E. H. Brown
NTNeil Thomas
Neil Thomas
KHKeino Hutchinson
Keino Hutchinson
KGKathleen M. Giacomini
Kathleen M. Giacomini
Genetic variants in SLC22A5 , encoding the membrane carnitine transporter OCTN2, cause the rare metabolic disorder Carnitine Transporter Deficiency (CTD). CTD is potentially lethal but actionable if detected early, with confirmatory diagnosis involving sequencing of SLC22A5 . Interpretation of missense variants of uncertain significance (VUSs) is a major challenge. In this study, we sought to characterize the largest set to date ( n = 150) of OCTN2 variants identified in diverse ancestral populations, with the goals of furthering our understanding of the mechanisms leading to OCTN2 loss-of-function (LOF) and creating a protein-specific variant effect prediction model for OCTN2 function. Uptake assays with 14 C-carnitine revealed that 105 variants (70%) significantly reduced transport of carnitine compared to wild-type OCTN2, and 37 variants (25%) severely reduced function to less than 20%. All ancestral populations harbored LOF variants; 62% of green fluorescent protein (GFP)–tagged variants impaired OCTN2 localization to the plasma membrane of human embryonic kidney (HEK293T) cells, and subcellular localization significantly associated with function, revealing a major LOF mechanism of interest for CTD. With these data, we trained a model to classify variants as functional (>20% function) or LOF (<20% function). Our model outperformed existing state-of-the-art methods as evaluated by multiple performance metrics, with mean area under the receiver operating characteristic curve (AUROC) of 0.895 ± 0.025. In summary, in this study we generated a rich dataset of OCTN2 variant function and localization, revealed important disease-causing mechanisms, and improved upon machine learning–based prediction of OCTN2 variant function to aid in variant interpretation in the diagnosis and treatment of CTD.

13 February 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CHCheng-Chieh Hsu
Cheng-Chieh Hsu
BSBaohai Shao
Baohai Shao
JKJenny E. Kanter
Jenny E. Kanter
YHYi He
Yi He
TVTomas Vaisar
Tomas Vaisar
KBKarin E. Bornfeldt
Karin E. Bornfeldt

24 November 2020 in Biocomputing 2020
Verified
Conference Paper
Open access
GMGregory McInnes
Gregory McInnes
RARuss B Altman
Russ B Altman
Pharmacogenetics studies how genetic variation leads to variability in drug response. Guidelines for selecting the right drug and right dose for patients based on their genetics are clinically effective, but are widely unused. For some drugs, the normal clinical decision making process may lead to the optimal dose of a drug that minimizes side effects and maximizes effectiveness. Without measurements of genotype, physicians and patients may adjust dosage in a manner that reflects the underlying genetics. The emergence of genetic data linked to longitudinal clinical data in large biobanks offers an opportunity to confirm known pharmacogenetic interactions as well as discover novel associations by investigating outcomes from normal clinical practice. Here we use the UK Biobank to search for pharmacogenetic interactions among 200 drugs and 9 genes among 200,000 participants. We identify associations between pharmacogene phenotypes and drug maintenance dose as well as differential drug response phenotypes. We find support for several known drug-gene associations as well as novel pharmacogenetic interactions.